Torrey Pines Investment and Innovestor’s Life Science Fund announced the pre-seed funding and launch of Polku Therapeutics Oy.

Vaxxas’ high-density microarray patch (HD-MAP) technology uses an array of microprojections – invisible to the naked human eye – to deliver the vaccine to the skin via a small patch sitting inside a small applicator device. When applied to the skin, the patch delivers the vaccine to the abundant immune cells immediately below the skin surface.

Context Therapeutics Inc. today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95.

The national peak body for health and medical research and innovation, Research Australia has partnered with Australian biotech company, Vaxxas, to bring around 70 health innovators together with Government to identify policy solutions to support the uptake of Australian health innovations here at home.

Brisbane biotechnology company Vaxxas has reached a major manufacturing milestone, producing its 100th batch of needle-free vaccine patches at Australia’s Translational Research Institute (TRI) – technology that may soon play an important role in protecting Australians against infectious diseases.

Context Therapeutics Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody.

Context Therapeutics Inc. today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds of approximately $100.0 million.

Leap Therapeutics, Inc. today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share.

Vaxxas President and Chief Executive Officer, David Hoey, moderated this sold-out session at 2 pm EDT on 1 April 2024 at the World Vaccine Congress in Washington, DC, USA.

The gala event, hosted in the new Australian Embassy at Scott Circle, shone a light on Australian excellence in areas of bilateral importance, including Science, Technology, Cyber Security, Sports and Culture. Each of the awardees is a leader in their field, and a proud representative for Australia on the international stage.

Leap Therapeutics, Inc. today announced new data from Part A of the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC).

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa.

Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication.

CEPI to provide up to USD4.3 million (AUD6.4 million) to Vaxxas to advance development of its high-density microarray patch for mRNA vaccines.

Leap Therapeutics, Inc. and Flame Biosciences, Inc., a privately-held biotechnology company, today announced that the companies have entered into a definitive merger agreement.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the Phase 2 DeFianCe study evaluating DKN-01.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the randomized controlled Part C of the ongoing DisTinGuish study to evaluate DKN-01.

Vaxxas will receive an AU$8.2 million second round grant as part of the Australian Federal Government’s Modern Manufacturing Initiative (MMI) to support the manufacturing scale-up of its potentially game-changing technology that enables vaccines to be applied to the skin using a small patch.

Leap Therapeutics, Inc., a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma (GEA) from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology (ESMO) Congress 2022 being held on September 9-12.